Catherine Boule
Direktor/Vorstandsmitglied bei ACTICOR BIOTECH SAS
Ursprung des Netzwerks ersten Grades von Catherine Boule
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 18 | |
Karista SAS
Karista SAS Investment ManagersFinance Karista SAS is an Independent Venture Capital firm founded in 2000. Cap Décisif Management SAS is headquartered in Paris, France.
9
| Private Company | Investment Managers | 9 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Axess Vision Technology SA
Axess Vision Technology SA Medical SpecialtiesHealth Technology Axess Vision Technology SA designs, develops, produces and commercializes surgical equipment. It offers video endoscope and electro-therapeutic products. The company was founded by Olivier Brosset, Marc Malou, Olivier Fructus and Nicolas Mathieu in February 24, 2006 and is headquartered in Saint-Pierre-des-Corps, France.
6
| Holding Company | Medical Specialties | 6 |
Prestodiag SAS
Prestodiag SAS Miscellaneous Commercial ServicesCommercial Services Prestodiag SAS develops, manufactures and markets a life science developments platform aimed at reducing the time and effort to detect microbiological pathogens. Its products include MonoPresto and Detection Kits. The company was founded by Thierry Livache, Thibaut Mercey and Felix Piat in March 2012 and is headquartered in Villejuif, France.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Incepto Medical SAS
Incepto Medical SAS Packaged SoftwareTechnology Services Incepto Medical SAS develops and distributes artificial intelligent (AI) based medical imaging applications. It offers solutions for computed tomography (CT) scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion. The company was founded by Antoine Jomier, Florence Moreau, Vincent Barrau, Jean Michel Malbrancq, and Gaspard d’Assignies and is headquartered in Paris, France.
4
| Holding Company | Packaged Software | 4 |
WatchFrog SA
WatchFrog SA Medical SpecialtiesHealth Technology Watchfrog SA creates and markets solutions for the in vivo detection of chemical, pharmaceutical and cosmetic substances. The firm offers to incorporate in vivo significance to early in vitro stage of drug discovery. It also offers biotechnological tools to accelerate environmental risk assessment. The company was founded by Barbara Demeneix and Gregory Lemkine in 2005 and is headquartered in Evry, France.
2
| Holding Company | Medical Specialties | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Catherine Boule
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ALCON INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
SANOFI | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Alcon Laboratories, Inc.
Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Sofimac Innovation SAS
Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector. | Investment Managers | Private Equity Investor Director/Board Member | |
ATON | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Founder Director/Board Member | |
CROSSJECT | Medical Specialties | Director/Board Member Director/Board Member | |
Massachusetts Institute of Technology | College/University | Masters Business Admin Graduate Degree | |
McMaster University | College/University | Corporate Officer/Principal | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Founder | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member | |
University of Zurich | College/University | Doctorate Degree | |
Swiss Federal Institute of Technology | College/University | Graduate Degree | |
Université Paris Dauphine-PSL | College/University | Undergraduate Degree Graduate Degree | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
London Business School | College/University | Masters Business Admin Masters Business Admin | |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
INSERM Transfert Initiative SAS
INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Investment Managers | Chairman Chairman | |
VOLUNTIS S.A. | Packaged Software | Director/Board Member Director/Board Member | |
Minka Therapeutics SA
Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
SENSORION | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Swiss Biotech Association operates as an industry association. The private company is based in Zurich, Switzerland. Michael Altorfer has been the CEO of the Swiss company since 2018. | Miscellaneous Commercial Services | President | |
PIXIUM VISION | Medical Specialties | Director/Board Member | |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
THERANEXUS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Tissium SA
Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Microphyt SA
Microphyt SA BiotechnologyHealth Technology Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France. | Biotechnology | Director/Board Member Director/Board Member | |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
LYSOGENE | Miscellaneous Commercial Services | Director/Board Member | |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member | |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
Revolo Biotherapeutics Ltd.
Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor | |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NH THERAGUIX SAS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Biotechnology | Founder | |
Agile Capital Markets SAS | Chief Executive Officer | ||
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistik
International
Frankreich | 25 |
Schweiz | 12 |
Belgien | 6 |
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 3 |
Sektoral
Health Technology | 30 |
Commercial Services | 10 |
Consumer Services | 7 |
Finance | 5 |
Technology Services | 2 |
Operativ
Director/Board Member | 222 |
Corporate Officer/Principal | 56 |
Chief Tech/Sci/R&D Officer | 25 |
Private Equity Investor | 25 |
Founder | 24 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
François Miceli | 43 |
Alain Munoz | 38 |
Célia Hart | 36 |
Alain Parthoens | 29 |
Chahra Khaoua Epouse Louafi | 26 |
François Thomas | 25 |
Guy Heynen | 17 |
Gerald D. Cagle | 15 |
Jérôme Snollaerts | 15 |
Dominik Escher | 15 |
Yannick Plétan | 14 |
Gilles Avenard | 11 |
Geoffroy Dubus | 10 |
Ohad Hammer | 10 |
Leila Nicolas | 9 |
- Börse
- Insiders
- Catherine Boule
- Unternehmensverbindungen